Filgotinib became the first advanced therapy to be recommended by NICE for treatment of patients with active moderate RA (DAS28-CRP >3.2 to ≤5.1) [4], followed by upadacitinib [5], adalimumab, etanercept (all as monotherapy/with methotrexate [MTX]) and infliximab (with MTX) [6]. The gene discussed is CRP; the disease is rheumatoid arthritis.